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COPD (chronic obstructive pulmonary disease) is a chronic progressive inflammatory disease
characterised by limitations in lung airflow that is not fully reversible. The concentrations and
correlations of TNF-á, CXCL8, big ET-1 and hsCRP were investigated in healthy non-smokers,
healthy smokers and patients with COPD in order to study their possible role in the patho-
physiology of COPD. The concentrations of TNF-á, CXCL8 and big ET-1 were not statisti-
cally different between the experimental groups. No significant differences for the measured
analytes were found between smokers and the non-smokers in the control group. The Spear-
man coefficient of correlation between the concentrations of TNF-á and CXCL8 was r = 0.638
(p<0.0001). However, the concentration of hsCRP was significantly higher in patients with COPD
than in the control group (p = 0.0004). hsCRP proved to be a more sensitive diagnostic para-













COPD (chronic obstructive pulmonary disease) is, ac-
cording to the Global Initiative for COPD, a chronic pro-
gressive inflammatory disease characterised by limitations
in lung airflow that is not fully reversible.1 According to
the WHO, COPD could become until 2020 the third
most common cause of mortality in the world.2 The
pathophysiology of COPD is not completely understood.
The most common cause of COPD is tobacco smoke
(80 % of COPD patients) and, as other causes, there are
also air pollution, poor nutrition, professional risk at
work and genetic factors.3 Systemic inflammation seems
to be a risk factor for various complications that occur
during COPD, like atherosclerosis, cachexia and osteo-
porosis.4 Various mediators released from structural and
inflammatory cells in the lungs have been investigated
and they probably participate in the pathophysiology of
COPD.2
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TNF-á (tumor necrosis factor-á) is a glycoprotein, a
strong inflammatory cytokine which has a key role in in-
flammation.5 TNF-á induces the synthesis of IL-6 (inter-
leukin-6) and stimulates the release of acute phase reac-
tants from hepatocytes, activates macrophages, epithelial
and mesenchymal cells and induces chemokine produc-
tion.2,5,6 Tobacco smoke induces the release of TNF-á and
has an important role in the pathophysiology of COPD.2,6
TNF-á influences gene expression of CXCL8 (interleu-
kin-8) and ET-1 (endothelin-1) in human endothelial
cells, and participates in bronchoconstriction through se-
condary release of ET-1.7,8,9
ET-1, a 21 aminoacid peptide, is one of the most po-
tent known vasoconstrictors. ET-1 is cleaved from its pre-
cursor big ET-1 (38 aminoacids) by endothelin convert-
ing enzyme (ECE).10,11 ET-1 is present in human lungs
and has a potential role as a mediator in lung diseases
like asthma, pulmonary hypertension and COPD.12,13 ET-1
is presumed to participate in vasoconstriction, broncho-
constriction, remodelling of the airways, activation of
inflammation cells, mucus secretion and hyperreactivity
of the airways.8,12 Increased concentration of ET-1 found
in COPD patients in bronchoalveolar lavage, sputum and
serum supports the role of ETs as potential bronchocon-
strictors in the pathophysiology of this disease.14 An in-
crease of ET-1 in sputum and also a slight increase in
plasma was found in COPD patients with exacerbation
of the disease.15
CXCL8 (interleukin-8) is a glycoprotein from a group
of chemokines which chemotactically attracts neutrophil
granulocytes and, to a lesser extent, lymphocytes to the
inflammatory site.2,5 Epithelial cells from the airways and
macrophages probably release CXCL8 under the influen-
ce of TNF-á, IL-1â, lipopolysaccharides and bacterial pro-
ducts, some viruses, oxidative stress and tobacco smoke
extracts.2 COPD patients have increased concentration of
CXCL8 in sputum and serum, which correlates with the
neutrophil number.16 Cultivated epithelial cells obtained
by bronchoscopy from COPD patients show increased
synthesis of CXCL8 compared to cells from smokers.17
The concentration of CXCL8 is increased in plasma of
hospitalized COPD patients and correlates with muscle
weakness.18
CRP (C-reactive protein) is an acute phase reactant
and its concentration is increased in inflammatory disea-
ses.19 CRP is synthesised in hepatocytes under the influ-
ence of IL-6.19 CRP concentration increases in bacterial
infectious diseases and rheumatoid and malignant disea-
ses; currently, with ''high sensitivity'' assays CRP is in-
vestigated as a prognostic factor in cardiovascular disea-
ses present silent systemic inflammation, hence the
name hsCRP.19,20 hsCRP, as a systemic marker of inflam-
mation, is increased in stable COPD patients and in COPD
patients with complications when compared to healthy
controls.4
As we described above, there was a number of inve-
stigations dealing with the concentration of these inflam-
matory mediators in specimens like induced sputum or
bronchoalveolar lavage, and their results indicate a local
inflammatory process.14,15,21–23 However, it is known that
COPD is a disease with prominent systemic inflamma-
tory response.4,24 The aim of this study was to identify
whether the inflammatory process in stable COPD patients
is powerful enough to produce significant changes in the
selected inflammatory markers (TNF-á, CXCL8 and
hsCRP). The role and concentration of big ET-1 in the
peripheral circulation of COPD patients and relationship
between big ET-1 and the concentration of TNF-á,
CXCL8 and hsCRP have not been defined, as yet.
Therefore, we also investigated the concentration of big
ET-1 in plasma (half life ≈ 23 min), which is considered
to be a reliable indicator of the activation of ET-1 (half
life  7 min).25 Big ET-1 is not believed to be subject to




The study was performed on specimens from patients with
stable COPD (n = 27) or with exacerbations (n = 7) who
were treated at the Jordanovac University Hospital for Lung
Diseases, Zagreb. In the tested group there were n = 8 fe-
males and n = 26 males, thereof 6 non-smokers and 28 smo-
kers. Except COPD, 15 patients also had another disease:
hypertension (3), hypertension and angina pectoris (4),
post-infarction status (4), hypertension and post-infarction
status (1), osteoporosis (2) and stenocardia (1). Inclusion
criteria for COPD patients was clinical diagnosis of COPD
based on clinical features and spirometric findings (forced
expiratory volume in 1 second (FEV1) < 80 %). There were
16 patients with moderate (FEV1 = 50–80 %) and 18 with
severe COPD (FEV1 < 50 %). The control group consisted
of healthy volunteers: smokers (37) and non-smokers (23),
without any clinical signs of the disease and with normal
spirometric findings (FEV1 > 80 %). Venous blood was col-
lected with K3EDTA as anticoagulant for big ET-1 and hsCRP
measurement and then centrifuged at 3000 g for 10 min,
plasma was aliquoted and frozen at –20 °C until measure-
ment. Venous blood for the measurement of TNF-á and
CXCL8 was collected in vacutainer tubes without anti-
coagulant and, after coagulum formation, was centrifuged
at 1000 g for 10 min, and serum was aliquoted and frozen
at –20 °C until measurement. The study was approved by
the Ethics Committee of the Jordanovac University Hospi-
tal for Lung Diseases and written informed consent was ob-
tained from each participant.
Methods
Clinical evaluation of the examinees included medical his-
tory and spirometric analysis of lung function. The concen-
tration of big ET-1 was determined with an ELISA test (Big
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endothelin, Enzyme Immunoassay for the Quantitative De-
termination of Human Big Endothelin, Biomedica Gruppe)
and the measuring range was 0.05–15.6 fmol/mL. hsCRP
concentration was measured nephelometrically on an BN
Pro Spec II nephelometer (N High Sensitivity CRP assay,
Dade Behring). The analytical sensitivity of this assay was
0.159 mg/L. The measurements of TNF-á and CXCL8 were
done using ELISA tests (Quantikine, Human IL-8 Immuno-
assay, R&D Systems; Quantikine Human TNF-á/TNFSF1A
Immunoassay, R&D Systems). The analytical sensitivity was
0.5–5.5 pg/mL for the TNF-á test, and 1.5–7.5 pg/mL for
CXCL8 test (data provided by manufacturer). Calibrators
and control samples were commercially available from the
same companies.
Subjects were divided in three groups: COPD patients
smokers and non-smokers, healthy smokers and healthy
non-smokers which served as a control group (Table I).
Statistical Analysis
Statistical analysis was performed by using the statistical
software MedCalc, version 7.0.1.0. All data were tested for
normal distribution with Kolmogorov-Smirnov test. The data
for all measured analytes did not show normal distribution
so results are presented as a median and the 25th–75th per-
centile. Figures present the median of the measured analytes
and the 25th–75th percentile and outliers (Box and whisker
plots). Statistical significance between groups was tested with
the Mann-Whitney U test in relation to the control group
(healthy non-smokers). The Spearman coefficient of correla-
tion was used to study the relationship between the measur-
ed parameters. Values p<0.05 were considered statistically
significant.
RESULTS
In this study we measured the concentrations and corre-
lation of TNF-á, CXCL8, big ET-1 and hsCRP in healthy
non-smokers, healthy smokers and patients with COPD
(Table II, Table III and Figure 1).
Patients with COPD had a statistically significant
increase in hsCRP (p = 0.0004), while healthy smokers
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TABLE I. Clinical characteristics of the studied groups(a)
COPD patients Smokers Non-smokers
Age / y 67 (64–72) 52 (45–58) 44 (40–59)
Smoking history (Pack/year) 45 (33–68) 28 (21–41) 0
FEV1 / % 44 (40–65) > 80 > 80
Lkc counts / 109 dm–3 7.50 (6.54–8.70) 6.60 (5.40–7.73) 5.55 (4.80–6.90)
Medication Yes No No
(a) Data are presented as a median and 25th–75th percentile in parenthesis.
TABLE II. Concentration (g) of measured analytes in serum (hsCRP, big ET-1) and plasma (TNF-á, CXCL8) of COPD patients, smokers and
non-smokers (control group)(a)
COPD patients Smokers Non smokers
g(TNF-á) / (pg mL–1) 11.6 (7.7–15.3) 15.0 (11.4–20.9) 12.8 (10.0–24.9)
g(CXCL8) / (pg mL–1) 33.8 (20.5–63.5) 29.4 (17.6–49.9) 29.7 (21.6–52.2)
g(Big ET-1) / (fmol mL–1) 0.80 (0.70–1.14) 1.10 (0.90–1.50) 1.00 (0.76–1.20)
g(hsCRP) / (mg L–1) 3.9 (1.52–5.39)(b) 1.52 (0.79–3.74) 1.10 (0.61–1.53)
(a) Data are presented as a median and 25th–75th percentile in parenthesis.
(b) p = 0.0004.
TABLE III. Concentration (g) of measured analytes in serum (hsCRP, big ET-1) and plasma (TNF-á, CXCL8) in moderate (FEV1>50 %) and
severe (FEV1 ≤ 50 %) COPD patients(a)
COPD patients
FEV1>50 % FEV1≤50 %
g(TNF-á) / (pg mL–1) 13.5 (7.45–19.65) 11.60 (7.75–19.60)
g(CXCL8) / (pg mL–1) 31.20 (19.45–113.38) 44.90 (18.88–73.38)
g(Big ET-1) / (fmol mL–1) 0.80 (0.70–1.35) 0.80 (0.60–1.10)
g(hsCRP) / (mg L–1) 4.90 (1.19–14.43) 3.90 (1.87–5.36)
(a) Data are presented as a median and 25th–75th percentile in parenthesis.
had no increase compared to the control group (p =
0.1134). Fifteen COPD patients with increased hsCRP
concentration (>3 mg/L) had additional complication (hy-
pertension, angina pectoris, osteoporosis) and/or exacer-
bation of COPD, but five patients without any signs of
complication and/or exacerbation also had elevated va-
lues of hsCRP. In comparison to severe COPD, patients
with moderate COPD showed no statistically significant
difference in hsCRP concentration (p = 0.5649). We also
found a correlation between hsCRP concentration and
smoking habit (pack/years) (r = 0.325, p = 0.0229). The
concentration of big ET-1 was not statistically different
in the COPD group (p = 0.3641), or in the group of heal-
thy smokers (p = 0.1565) compared to the control group. In
our study, there was no increase in TNF-á concentration
in the sera of COPD patients (p = 0.0788) or in healthy
smokers (p = 0.6472) compared to the control group. Com-
pared to the control group, the concentration of CXCL8
in the sera of COPD patients was not statistically different
(p = 0.4839). Also, there was no change in the concen-
tration of CXCL8 in healthy smokers compared to the con-
trol group (p = 0.8717). In our study, we did not find any
correlation between the concentration of CXCL8 and neu-
trophils in the peripheral concentration (results not shown).
Serum concentrations of TNF-á and CXCL8 showed
(Figure 2) a statistically significant correlation (r = 0.638;
p<0.0001). Our results also showed a certain correlation
between the concentrations of big ET-1 and CXCL8 (r =
0.381; p = 0.0007). Correlation between other measured
parameters was not found (results not shown).
DISCUSSION
A statistically significant increase was found in hsCRP
concentration in the plasma of COPD patients as com-
pared to the control group (healthy non-smokers). How-
ever, the concentrations of TNF-á, CXCL8 and big ET-1
in COPD patients did not exceed the values established
for the control group. The concentrations of all four media-
tors were not statistically different in specimens of healthy
smokers from those of the control group. A positive cor-
relation was found between some mediators (TNF-á and
CXCL8, and big ET-1 and CXCL8), which supports the
assumption about interaction of these mediators in inflam-
matory process.
Systemic inflammation was present in COPD patients,
which is supported by the fact that hsCRP was increased
in systemic circulation in patients with stable and unstab-
le COPD, and also in COPD patients with complications
like atherosclerosis and osteoporosis. Increased values of
hsCRP in stable COPD patients, determined regardless
of complications or COPD exacerbation, confirmed the
presence of systemic inflammation, which is in accor-
dance with studies by other authors.4 Man et al. found
increased values of hsCRP in their prospective longitu-
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Figure 1. Concentrations (g) of (a) hsCRP (b) big ET-1 (c) TNF-á
(d) CXCL8 in healthy non-smokers (control group), healthy smo-
kers and patients with COPD presented as box and whisker plots
(*, p< 0.05).
dinal study and assumed hsCRP as a good predictor for
mortality and cardiovascular events in patients with mild
to moderate COPD.26 Significantly increased hsCRP in
plasma was also recorded in COPD patients without is-
haemic heart disease.20 The correlation between hsCRP
concentration and smoking habit (pack/years) supports the
assumption that tobacco smoke has an influence on sys-
temic inflammation.27 hsCRP indicates that COPD is a
systemic inflammatory disease, and it could serve as a
predictor for exacerbations.28 Although COPD patients are
mostly smokers, a small number of non-smokers also de-
velop COPD, suggesting that there are also certain ge-
netic components of the disease.2
Based on the results achieved by measuring the con-
centrations of TNF-á, CXCL8 and big ET-1 in peripheral
circulation, it was not possible to demonstrate systemic
inflammation in COPD.
Local effects of big ET-1, i.e. its half life and also
the cleaving to ET-1 by ECE, can actually be some of
the reasons why we did not find any change in the con-
centration of big ET-1 in circulation.13,25 There was also
no increase in cytokines like TNF-á and chemokines
CXCL8 in our study; since some authors reported that
they probably induce the expression of the endothelin sy-
stem, we supposed that the release of big ET-1 was not
induced.7,8 TNF-á has a role in the mRNA expression of
CXCL8 and ET-1 in human endothelial cells and in non-
small lung cancer.7,29 Our results also show a certain
correlation between the concentrations of big ET-1 and
CXCL8. However, it is not clear if big ET-1 release was
induced by CXCL8, or vice versa. In in vitro experiments
on endothelial cells, CXCL8 did not show any influence
on the mRNA expression of ET-1 and ECE.8 The studies
done on melanoma cells showed that ET-1 induced the
release of CXCL8.30 Zheng et al. did not demonstrate
any correlation between ET-1, CXCL8 and TNF-á in the
serum of patients with bronchoectiasis.31
The negative results obtained for TNF-á and CXCL8
were in line with some results published previously. In
peripheral circulation of COPD patients with malnutri-
tion, there was no increase in TNF-á and leptin; it was
also not recorded in COPD patients with exacerbations
or stable COPD.32 Calikoglu et al. found an increase in
the concentration of TNF-á only in the sera of COPD
patients with exacerbations, and Vernooy et al. found an
increase in the concentration of soluble TNF-á receptors,
while the concentration of TNF-á was within the refe-
rence range for healthy individuals.33,34 Broekhuizen et
al. found measurable values of TNF-á in sputum but not
in the plasma of COPD patients.35 Possible explanation
for the unchanged concentration of TNF-á is its local and
short-term effect, its degradation and its half life of
aproximately 6–7 min, as well as its binding to receptors
and renal clearance.5,24
Vernooy et al. found measurable values of CXCL8
in the plasma of four of 18 COPD patients and a statisti-
cally significant increase in the sputum when compared
to healthy volunteers, which is explained by the fact that
the regulation of local and systemic inflammatory res-
ponse in COPD is different.34 In the literature, we found
that CXCL8 was mostly measured in the sputum of COPD
patients.21,22,23 Results of such measurements indicated a
correlation between CXCL8 concentration and the num-
ber of neutrophils and eosinophils; the increased values
are in accordance with the level of obstruction of the air-
ways and it was thought that they could serve to assess
inflammmation in the airways.16,21 In our study, we did not
find any correlation between the concentration of CXCL8
and neutrophils, which may be explained by the fact that
this chemokine acts rather locally and thus attracts neu-
trophils to the local inflammatory site.5
The correlation found between TNF-á and CXCL8
confirmed that TNF-á, as one of the most important pro-
inflammatory cytokines, induces the release of the che-
mokine CXCL8 and in this way contributes to chemo-
taxis of neutrophils to the inflammatory site.2,5
Local increase and the role of these mediators in
COPD cannot be excluded based on our results. Some
authors thought that systemic inflammatory response in
COPD was not associated with local inflammation which
takes place in the lungs.4,24 hsCRP is synthetized in he-
patocytes and has a long plasma half-life (19 h), as oppos-
ed to other measured mediators in this study.19 However,
some COPD patients were on therapy with corticosteroids
and inhalators and some of them were on antihypertensive
medications, which could also have an impact on the re-
sults of determination of the inflammatory mediators stat-
ed above.36 However, regulation pathways between in-
flammation and endothelial functions are not yet clear and
further in vivo and in vitro investigations are necessary
to gain insight in interactions between these parameters,
and the possible influence of tobacco smoke.
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Figure 2. Plot of correlation for serum concentrations (g) of CXCL8
and TNF-á presented by correlation coefficient (r) = 0.638, and
level of significance p<0.0001; 95 % CI for r = 0.4889 to 0.7512.
CONCLUSION
On the basis of our results and the reviewed literature,
we can conclude that hsCRP is a valuable marker for di-
sease follow-up and a predictor of COPD progression.
Nevertheless, further investigations are needed for com-
parisons of systemic and local inflammatory markers in
COPD, as well as in vitro studies of regulatory pathways
and the manner of inducing cytokine, chemokine and en-
dothelin release. The development of new potential tera-
peutic targets like antagonists of TNF-á, CXCL-8 and
ET-1 will probably indicate the need for their local ad-
ministration in the lungs.37
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SA@ETAK
TNF-á, CXCL8, veliki ET-1 i hsCRP u bolesnika s kroni~nom opstrukcijskom plu}nom bolesti
Sanja Marevi}, József Petrik, Nada Vrki}, Sanja Popovi}-Grle, Tihana @ani}-Grubi{i} i Ivana ^epelak
Kroni~na opstrukcijska plu}na bolest (KOPB; engl. Chronic Obstructive Pulmonary Disease, COPD) je
progresivna kroni~na upalna bolest karakterizirana ireverzibilnim smanjenjem protoka zraka kroz di{ne puteve.
Cilj ovoga rada bio je ispitati koncentracije i korelaciju faktora tumorske nekroze-a (engl. Tumor Necrosis Fac-
tor-a, TNF-á), interleukina-8 (CXCL8), velikog endotelina-1 (engl. big endothelin-1, big ET-1) i visoko
osjetljivog C-reaktivnog proteina (engl. high sensitive C-Reactive Protein, hsCRP) u zdravih nepu{a~a, zdravih
pu{a~a i bolesnika s KOPB te ispitati njihovu ulogu u patofiziologiji KOPB i sistemskoj upali. Koncentracija
hsCRP bila je statisti~ki zna~ajno ve}a u bolesnika s KOPB nego u kontrolnoj skupini (p = 0,0004), dok se
koncentracija TNF-á (p = 0,0788), CXCL8 (p = 0,4839) i velikog ET-1 (p = 0,3641) nije statisti~ki zna~ajno
razlikovala. Nije na|ena statisti~ki zna~ajna razlika za izmjerene analite izme|u pu{a~a i kontrolne skupine.
Spearmanov koeficijent korelacije za koncentraciju TNF-á i CXCL8 iznosio je r = 0,638 (p<0,0001). hsCRP se
pokazao kao osjetljiviji dijagnosti~ki parametar u usporedbi s TNF-á, CXCL8 i velikim ET-1 u sistemskoj cir-
kulaciji bolesnika s KOPB.
TNF-á, CXCL8, BIG ET-1 AND hsCRP IN COPD 217
Croat. Chem. Acta 81 (1) 211¿217 (2008)
